News Beeline raises $300m for BMS drugs, and other biofinancings Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.
News Novo Nordisk joins molecular glue club with Neomorph deal Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t
News FDA won't approve Summit, Akeso's ivonescimab The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.